RxDoctor Payments Data

James Handtke, DO

Family Medicine · Middlebury, INNPI 1033748710

Payments from drug & device makers

$959in general payments, 2019–2025

Across 42 payments — averaging $22.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$291
  • Novo Nordisk$209
  • AstraZeneca$185
  • Lilly USA, LLC$87
  • Exact Sciences$49
  • Dexcom, Inc.$39
  • plus $98 from 4 others

What the payments were for

  • Food & beverage$77481%
  • Education$18519%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$959 in reported general payments places this provider in the 60th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$72,012
Medicare patients
168
Services billed
1,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide111$124,147
JardianceEmpagliflozin66$71,901
TrulicityDulaglutide24$23,560
EliquisApixaban22$16,074
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$14,803
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$12,407
Breo ElliptaFluticasone/Vilanterol19$12,038
MounjaroTirzepatide11$11,418
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$8,836
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$5,228
SymbicortBudesonide/Formoterol Fumarate18$4,654
Novolog FlexpenInsulin Aspart16$4,098
Gabapentin113$1,903
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen29$1,900
Albuterol Sulfate HfaAlbuterol Sulfate82$1,876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$209$124,147111 claims
Boehringer IngelheimJardiance$37$71,90166 claims
Lilly USA, LLCTrulicity, Mounjaro$87$34,97835 claims
AstraZenecaSymbicort$185$4,65418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Middlebury

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →